Literature DB >> 25342714

Heparin-independent, PF4-dependent binding of HIT antibodies to platelets: implications for HIT pathogenesis.

Anand Padmanabhan1, Curtis G Jones2, Daniel W Bougie3, Brian R Curtis4, Janice G McFarland5, Demin Wang6, Richard H Aster7.   

Abstract

Antibodies specific for platelet factor 4 (PF4)/heparin complexes are the hallmark of heparin-induced thrombocytopenia and thrombosis (HIT), but many antibody-positive patients have normal platelet counts. The basis for this is not fully understood, but it is believed that antibodies testing positive in the serotonin release assay (SRA) are the most likely to cause disease. We addressed this issue by characterizing PF4-dependent binding of HIT antibodies to intact platelets and found that most antibodies testing positive in the SRA, but none of those testing negative, bind to and activate platelets when PF4 is present without any requirement for heparin (P < .0001). Binding of SRA-positive antibodies to platelets was inhibited by chondroitinase ABC digestion (P < .05) and by the addition of chondroitin-4-sulfate (CS) or heparin in excess quantities. The findings suggest that although all HIT antibodies recognize PF4 in a complex with heparin, only a subset of these antibodies recognize more subtle epitopes induced in PF4 when it binds to CS, the major platelet glycosaminoglycan. Antibodies having this property could explain "delayed HIT" seen in some individuals after discontinuation of heparin and the high risk for thrombosis that persists for weeks in patients recovered from HIT.
© 2015 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25342714      PMCID: PMC4281824          DOI: 10.1182/blood-2014-06-580894

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

Authors:  J Amiral; F Bridey; M Dreyfus; A M Vissoc; E Fressinaud; M Wolf; D Meyer
Journal:  Thromb Haemost       Date:  1992-07-06       Impact factor: 5.249

2.  Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.

Authors:  Janice McFarland; Andrew Lochowicz; Richard Aster; Bryan Chappell; Brian Curtis
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

3.  Characterization of a chondroitin 4 -sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4 ) released from human blood platelets.

Authors:  A J Barber; R Käser-Glanzmann; M Jakábová; E F Lüscher
Journal:  Biochim Biophys Acta       Date:  1972-12-29

4.  Binding of platelet factor 4 to cultured human umbilical vein endothelial cells.

Authors:  C Busch; J Dawes; D S Pepper; A Wasteson
Journal:  Thromb Res       Date:  1980 Jul 1-15       Impact factor: 3.944

5.  Delayed-onset heparin-induced thrombocytopenia and thrombosis.

Authors:  T E Warkentin; J G Kelton
Journal:  Ann Intern Med       Date:  2001-10-02       Impact factor: 25.391

6.  Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia.

Authors:  D E Wallis; D L Workman; B E Lewis; L Steen; R Pifarre; J F Moran
Journal:  Am J Med       Date:  1999-06       Impact factor: 4.965

7.  Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody.

Authors:  Zhong Q Li; Weiyi Liu; Kwang S Park; Brue S Sachais; Gowthani M Arepally; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

8.  Characterization of a heparan sulfate and a peculiar chondroitin 4-sulfate proteoglycan from platelets. Inhibition of the aggregation process by platelet chondroitin sulfate proteoglycan.

Authors:  H B Nader
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

9.  A diagnostic test for heparin-induced thrombocytopenia.

Authors:  D Sheridan; C Carter; J G Kelton
Journal:  Blood       Date:  1986-01       Impact factor: 22.113

10.  Purification and characterization of human platelet proteoglycan.

Authors:  M Okayama; K Oguri; Y Fujiwara; H Nakanishi; H Yonekura; T Kondo; N Ui
Journal:  Biochem J       Date:  1986-01-01       Impact factor: 3.857

View more
  20 in total

Review 1.  Induction of anti-PF4/heparin antibodies after arthroplasty for rheumatic diseases.

Authors:  Kiyoshi Migita; Tomoyuki Asano; Shuzo Sato; Satoru Motokawa
Journal:  Fukushima J Med Sci       Date:  2018-04-07

2.  A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis.

Authors:  Anand Padmanabhan; Curtis G Jones; Brian R Curtis; Daniel W Bougie; Mia J Sullivan; Namrata Peswani; Janice G McFarland; Daniel Eastwood; Demin Wang; Richard H Aster
Journal:  Chest       Date:  2016-02-19       Impact factor: 9.410

3.  A modified PF4-dependent, CD62p expression assay selectively detects serotonin-releasing antibodies in patients suspected of HIT.

Authors:  Anand Padmanabhan; Curtis G Jones; Daniel W Bougie; Brian R Curtis; Janice G McFarland; Demin Wang; Richard H Aster
Journal:  Thromb Haemost       Date:  2015-07-16       Impact factor: 5.249

4.  Screening frequency, incidence and pattern of heparin-induced thrombocytopenia syndrome at a large tertiary institution.

Authors:  Hae Tha Mya; Hui Ming Tay; Shien Wen Gan; Shilpa Surendran; Shu Hui Yeang; Cynthia Ciwei Lim; HuiLin Choong; Lai Heng Lee; Heng Joo Ng
Journal:  Int J Hematol       Date:  2016-04-22       Impact factor: 2.490

5.  Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia.

Authors:  Mehraboon Irani; Eric Siegal; Abhay Jella; Richard Aster; Anand Padmanabhan
Journal:  Transfusion       Date:  2018-12-17       Impact factor: 3.157

6.  Regulatory T Cells Control PF4/Heparin Antibody Production in Mice.

Authors:  Yongwei Zheng; Wen Zhu; Dipica Haribhai; Calvin B Williams; Richard H Aster; Renren Wen; Demin Wang
Journal:  J Immunol       Date:  2019-08-30       Impact factor: 5.422

7.  A Platelet Factor 4-Dependent Platelet Activation Assay Facilitates Early Detection of Pathogenic Heparin-Induced Thrombocytopenia Antibodies.

Authors:  Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Mehraboon S Irani; Binod Dhakal; Brenda Pierce; Richard H Aster; Anand Padmanabhan
Journal:  Chest       Date:  2017-10       Impact factor: 9.410

Review 8.  Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Authors:  Gowthami M Arepally; Anand Padmanabhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

9.  Reduced induction of anti-PF4/heparin antibody in RA patients after total knee arthroplasty.

Authors:  Masahiro Izumi; Tatsuya Sakai; Atsunori Shirakawa; Hideko Kozuru; Yuka Jiuchi; Yasumori Izumi; Tomohiko Asahara; Kenji Kumagai; Masaaki Mawatari; Makoto Osaki; Satoru Motokawa; Kiyoshi Migita
Journal:  Arthritis Res Ther       Date:  2016-08-25       Impact factor: 5.156

10.  A prospective, blinded study of a PF4-dependent assay for HIT diagnosis.

Authors:  Bethany Samuelson Bannow; Deepti M Warad; Curtis G Jones; Shannon M Pechauer; Brian R Curtis; Daniel W Bougie; Ruchika Sharma; Diane E Grill; Mary W Redman; Parisa R Khalighi; Rachel R Leger; Rajiv K Pruthi; Dong Chen; Daniel E Sabath; Richard H Aster; David A Garcia; Anand Padmanabhan
Journal:  Blood       Date:  2021-02-25       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.